Cells For Potential Therapeutic Suppliers & Manufacturers

Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is ...

Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...

We are a biotech company combining microfluidics, digitalization and bioengineering to make high quality biological therapies at affordable cost and minimized environmental impact. Therapeutic cells can multiply in the patient's body. This allows ...

Curadigm is an early-stage company focused on shifting the paradigm of therapeutic clearance, bioavailability, and efficacy to improve treatment outcomes for millions of patients. Curadigm was spun-off from Nanobiotix, a late-stage clinical company, ...

Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...

Lilly was founded in 1876 by Colonel Eli Lilly, a man committed to creating high-quality medicines that met real needs in an era of unreliable elixirs peddled by questionable characters. His charge to the generations of employees who have followed ...